Dr. Douglas Fraker is Chief of the Division of Endocrine and Oncologic Surgery as well as a surgical oncologist and an endocrine surgeon, who was formally a senior investigator at the National Cancer Institute. Dr. Fraker’s research efforts have focused on regional perfusion to treat melanoma and soft tissue sarcomas of the extremities and metatastic tumors of the liver. His clinical practice deals primarily with surgical oncology (including melanoma, sarcoma, and liver tumors) and endocrine surgery of the thyroid, parathyroid, adrenal and pancreas. Clinical research protocols include isolated limb perfusion for melanoma and sarcoma, intra arterial chemotherapy for liver tumors, and photodynamic therapy for intra peritoneal disease. Research interests include mechanism of action of tumor necrosis factor, treatment strategy targeting tumor angiogenesis, regional gene therapy, and photodynamic therapy.

Special Interests:
Treatment of primary and metastatic liver tumors by resection, radiofrequency thermal ablation, intra-arterial pump for chemotherapy; and sentinel lymph node mapping; treatment of melanoma with sentinel lymph node mapping and biopsy, and isolated limb perfusion; gastrointestinal cancers of the esophagus, stomach, colon and rectum; thyroid cancer; parathyroid disease; pancreatic islet cell tumors; carcinoid; adrenal tumors including laparoscopic adrenalectomy; gastrointestinal sarcomas; use of photodynarnic therapy for treatment of intraperitoneal malignancies (carcinomatosis and sarcomatosis, including ovarian cancer).